kari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor "What This Means" interview focused on the Company's recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

During the interview, Mr. Gaslightwala highlighted the significance of Akari's first ASCO abstract acceptance and discussed newly presented preclinical data demonstrating combination synergy between Akari's differentiated spliceosome-modulating ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models. The data further supports the potential of Akari's proprietary PH1 payload platform to address the most difficult-to-treat cancers with significant unmet met, such as KRAS-driven tumors.